![]() On September 9, 2022, FDA approved ROLVEDON™ (formerly known as Rolontis)(eflapegrastim-xnst) injection indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. ![]() The divestiture of seven marketed products infused non-dilutive capital back into the organization and enabled Spectrum to further advance its two cornerstone, value driving assets.Īs of 2023, Spectrum has one FDA approved drug (ROLVEDON™ (eflapegrastim) is also formerly known as Rolontis) and one drug in advanced development (Poziotinib). The products sold were Fusilev (levoleucovorin), Folotyn (pralatexate injection), Zevalin (ibritumomab tiuxetan), Marqibo (vincristine sulfate LIPOSOME injection), Beleodaq (belinostat) for injection, Evomela (melphalan) for injection, and Khapzory (levoleucovorin). The seven drugs had a combined sales of $76.4 million in the first three quarters of 2018. In January 2019, Spectrum Pharmaceuticals sold its entire portfolio of hematology and oncology related products to Acrotech Biopharma USA, Inc., a New Jersey-based subsidiary of India's Aurobindo Pharma Ltd. It develops and markets drugs for treatments in hematology and oncology.Īfter a deal valued at $248 million was announced in April 2023, Assertio Holdings announced that it had completed its acquisition of the Massachusetts-based company on July 31. Spectrum Pharmaceuticals is an American biopharmaceutical company located in Boston, MA.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |